His primary areas of study are Internal medicine, Endocrinology, Neuroscience, Striatum and Dopamine. His Endocrinology research incorporates themes from Agonist, SCH-58261 and Adenosine A2A receptor. Per Svenningsson has included themes like Receptor and Long-term depression in his Neuroscience study.
His work deals with themes such as Antidepressant and Hippocampus, which intersect with Receptor. His Striatum research is multidisciplinary, relying on both Calmodulin, Neurodegeneration, Cytochrome c oxidase and Mass spectrometry. His studies deal with areas such as Pharmacology and Protein kinase A, Phosphorylation as well as Dopamine.
Per Svenningsson mostly deals with Internal medicine, Parkinson's disease, Endocrinology, Neuroscience and Receptor. His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology. His Parkinson's disease research is multidisciplinary, incorporating perspectives in Biomarker and Parkinsonism.
His work carried out in the field of Endocrinology brings together such families of science as Agonist, Adenosine A2A receptor and Serotonin. His Neuroscience research includes themes of AMPA receptor and Neurotransmission. Per Svenningsson interconnects Pharmacology and Cell biology in the investigation of issues within Receptor.
The scientist’s investigation covers issues in Parkinson's disease, Internal medicine, Disease, Neuroscience and Dopamine. His Parkinson's disease research incorporates elements of Dementia, Dopaminergic, Neurodegeneration and Parkinsonism. As part of the same scientific family, Per Svenningsson usually focuses on Neurodegeneration, concentrating on Cell biology and intersecting with Receptor.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Endocrinology and Oncology. His Endocrinology study combines topics from a wide range of disciplines, such as Phenotype and Dyskinesia. The various areas that Per Svenningsson examines in his Neuroscience study include Schizophrenia and Neurotransmission.
Per Svenningsson mainly focuses on Parkinson's disease, Pathology, Atrophy, Neurology and Disease. Per Svenningsson interconnects Dopaminergic, Cognition, Neuroscience, Immunology and Biomarker in the investigation of issues within Parkinson's disease. Per Svenningsson's looking at Dopaminergic as part of his Endocrinology and Internal medicine and Dopaminergic study.
His research integrates issues of Index finger and Progressive neurodegeneration in his study of Neuroscience. His study in the fields of Disease specific under the domain of Disease overlaps with other disciplines such as Knowledge acquisition. He works mostly in the field of Dopamine, limiting it down to topics relating to Agonist and, in certain cases, Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Adenosine and Brain Function
Bertil B Fredholm;Jiang-Fan Chen;Rodrigo A Cunha;Per Svenningsson.
International Review of Neurobiology (2005)
DARPP-32: an integrator of neurotransmission.
Per Svenningsson;Akinori Nishi;Gilberto Fisone;Jean-Antoine Girault.
Annual Review of Pharmacology and Toxicology (2004)
Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum
Emmanuel Valjent;Vincent Pascoli;Per Svenningsson;Surojit Paul.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Alterations in 5-HT1B Receptor Function by p11 in Depression-Like States
Per Svenningsson;Karima Chergui;Ilan Rachleff;Marc Flajolet.
Science (2006)
Distribution, biochemistry and function of striatal adenosine A2A receptors
Svenningsson P;Le Moine C;Fisone G;Fredholm Bb.
Progress in Neurobiology (1999)
Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5
James A. Bibb;Jingshan Chen;Jane R. Taylor;Per Svenningsson.
Nature (2001)
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Per Svenningsson;Eric Westman;Clive Ballard;Dag Aarsland;Dag Aarsland;Dag Aarsland.
Lancet Neurology (2012)
Depression in Parkinson disease—epidemiology, mechanisms and management
Dag Aarsland;Sven Påhlhagen;Clive G. Ballard;Uwe Ehrt.
Nature Reviews Neurology (2012)
Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity
Paolo Calabresi;Paolo Gubellini;Diego Centonze;Barbara Picconi.
The Journal of Neuroscience (2000)
Diverse psychotomimetics act through a common signaling pathway.
Per Svenningsson;Eleni T. Tzavara;Robert Carruthers;Ilan Rachleff.
Science (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Rockefeller University
Karolinska Institute
King's College London
Karolinska Institute
Takeda (Japan)
Yale University
Stockholm County Council
Karolinska Institute
Karolinska Institute
Université Paris Cité
École Polytechnique Fédérale de Lausanne
University of Edinburgh
Vanderbilt University
Nanjing University of Science and Technology
Southern University of Science and Technology
Qatar University
University of California, San Diego
University of Minnesota
Tokyo Gakugei University
Technische Universität Braunschweig
University of Newcastle Australia
Universidade de São Paulo
Utah State University
University of Wisconsin–Madison
University of Porto
National Tsing Hua University